Novartis Profile

<div class='circular--portrait' style='background:#2A0CD0;color: white;font-size:4em;padding-top: 25px;;'>NO</div>


12 / 100

Odds of Distress

Equity ratings for Novartis AG are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting November 19, 2019 and ending today February 17, 2020. Click here to learn more.

Novartis Profile

Next fiscal quarter end is expected on March 31, 2020. Novartis AG, together with its subsidiaries, researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 103914 people. more on Novartis
Novartis Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Novartis AG SEC Filings
Novartis SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameNovartis AG
Older SymbolNVSEF
President CEOChris IlsleyView All
Thematic Classifications
Active investing themes Novartis currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Novartis AG
Piotroski F Score
Academic score to determine the current strength of Novartis AG financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Financial Strength
Novartis AG ability to generate sufficient cash flow to pay bills, repay debt, and make consistent year-to-year profit
Total Debt
Debt Current
Debt Non Current
Debt to Equity Ratio
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Return on Sales
Earnings per Basic Share
Earnings per Diluted Share
Price to Earnings Ratio
Earnings before Tax
Few selected profitability drivers of Novartis representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Income Tax Expense
Gross Margin
Profit Margin
Novartis AG (NVS) is traded on BATS Exchange in USA. It is located in Lichtstrasse 35 and employs 103,914 people. Novartis AG was previously known as NOVARTIS AG and was traded on BATS Exchange under the symbol NVSEF. Novartis is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 211.49 B. Novartis AG runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 2.27 B outstanding shares of which 4.03 M shares are now shorted by investors with about 2.87 days to cover shorted positions. NOVARTIS AG ADS has about 11.34 B in cash with 13.62 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.01.
Check Novartis Probability Of Bankruptcy

Ownership Allocation (%)

Novartis Target Price Odds Analysis

Odds Below 97.49HorizonTargetOdds Above 97.49
94.25%30 days 97.49 5.61%
Based on normal probability distribution, the odds of Novartis to move above current price in 30 days from now is about 5.61 (This Novartis AG probability density function shows the probability of Novartis Stock to fall within a particular range of prices over 30 days) .

Novartis AG Top Holders

Novartis AG Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Novartis Against Markets

Did you try this?

Run Price Exposure Probability Now


Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module

Novartis Upcoming and Recent Events

Novartis Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportApril 22, 2020
Next Earnings ReportJuly 16, 2020
Next Fiscal Quarter EndMarch 31, 2020
Next Fiscal Year EndFebruary 3, 2021
Last Quarter Report DateDecember 31, 2019
Last Earning Anouncement DateMarch 31, 2019

Novartis Corporate Filings

Novartis SEC Reporting

Unclassified Corporate Event

Novartis Corporate Directors

Ton Buechner Non-Executive Independent Director
Pierre Landolt Member of the Board of Directors
Elizabeth Doherty Non-Executive Independent Director
Additionally see Stocks Correlation. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Company logos by clearbit